Department of General Surgery and Transplantation, ASST Grande Ospedale Metropolitano Niguarda, Milan 20162, Italy.
World J Gastroenterol. 2021 Mar 14;27(10):928-938. doi: 10.3748/wjg.v27.i10.928.
The coronavirus disease 2019 (COVID-19) pandemic has upended healthcare systems worldwide and led to an inevitable decrease in liver transplantation (LT) activity. During the first pandemic wave, administrators and clinicians were obliged to make the difficult decision of whether to suspend or continue a life-saving procedure based on the scarce available evidence regarding the risk of transmission and mortality in immunosuppressed patients. Those centers where the activity continued or was heavily restricted were obliged to screen donors and recipients, design COVID-safe clinical pathways, and promote telehealth to prevent nosocomial transmission. Despite the ever-growing literature on COVID-19, the amount of high-quality literature on LT remains limited. This review will provide an updated view of the impact of the pandemic on LT programs worldwide. Donor and recipient screening, strategies for waitlist prioritization, and posttransplant risk of infection and mortality are discussed. Moreover, a particular focus is given to the possibility of donor-to-recipient transmission and immunosuppression management in COVID-positive recipients.
2019 年冠状病毒病(COVID-19)大流行使全球的医疗体系陷入混乱,并导致肝移植(LT)活动不可避免地减少。在第一波大流行期间,管理人员和临床医生根据关于免疫抑制患者传播风险和死亡率的稀缺证据,不得不做出艰难的决定,是暂停还是继续进行挽救生命的程序。那些继续进行或严格限制活动的中心,必须对供体和受者进行筛查,设计 COVID-安全的临床路径,并推广远程医疗,以防止医院内传播。尽管关于 COVID-19 的文献不断增加,但关于 LT 的高质量文献数量仍然有限。这篇综述将提供全球 LT 项目受大流行影响的最新观点。讨论了供体和受者筛查、等待名单优先级排序策略,以及移植后感染和死亡率的风险。此外,特别关注 COVID-阳性受者中供体向受者传播和免疫抑制管理的可能性。